Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ColoFast

Financiado

Cerrado

Developing a Non Invasive Kit for Early Colorectal Cancer Detection

Colorectal cancer (CRC) represents one of the most important health problems worldwide. Decreasing the mortality rate by CRC in Europe is a clear unmet need today. Medical community agrees that this number of CRC related deaths co... ver más

30/06/2021

ADVANCED MARKER DI...

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

ADVANCED MARKER DISCOVERY La investigación, el desarrollo, la producción, la comercialización y la distribución e importación de productos biotecnológicos, farmacéuti...

TRL 3-4 | 4M€

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-06-30

SMEInst-05-2016-2017: Supporting innovative SMEs in the h...

I+D

Cerrada hace 8 años

0% 88% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

ADVANCED MARKER DISCOVERY

2.82M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ColonScan A simple to use accurate and cost effective blood test for... 71K€ Cerrado

PDC2021-121444-I00 BIOSENSOR PARA MONITORIZACION DE BIOMARCADORES DE CANCER COL... 86K€ Cerrado

Colodetect Development of a novel blood based diagnostic test for color... 2M€ Cerrado

RTC-2015-4167-1 DESARROLLO DE UNA PLATAFORMA COMPLETA PARA EL ANÁLISIS DE CÉ... 849K€ Cerrado

ColoDix Disruptive and high accuracy test for early colorectal cance... 4M€ Cerrado

SME-2015-0640 Validation of a novel, high sensitive and more efficient non... 79K€ Cerrado

Duración del proyecto: 48 meses Fecha Inicio: 2017-06-23
Fecha Fin: 2021-06-30

Líder del proyecto

ADVANCED MARKER DISCOVERY La investigación, el desarrollo, la producción, la comercialización y la distribución e importación de productos biotecnológicos, farmacéuti...

TRL 3-4 | 4M€

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Colorectal cancer (CRC) represents one of the most important health problems worldwide. Decreasing the mortality rate by CRC in Europe is a clear unmet need today. Medical community agrees that this number of CRC related deaths could be prevented by adequate screening programs for early detection. European authorities look for new strategies to address the clinical need for early diagnosis of CRC that will reduce patient care associated costs. Potential savings would be achieved if CRC patients were diagnosed earlier. The objective of this proposal is to validate and commercialize a novel, non-invasive, simple to use kit (ColoFastTM), regulatory approved for the diagnosis of CRC in blood. It is based on a new generation of leading-edge biomarkers that showed very high sensitivity and specificity for early detection of CRC in two prospective cohorts. The commercialization of the kit will have clear impact in improving survival of patients and reducing mortality by CRC cancer, with significant costsavings for National Health Services. It will be easily implemented in the clinical routine of the majority of European hospitals, with better acceptance of patients. ColoFast represents a significant business opportunity, addressing a clear unmet medical need in a large and expanding target population of 189M people in Europe in 2020, growing at 25%, with a significant global market of €1,616M in Europe, the US and Japan this year. It will have a huge impact on the growth of a SME as Amadix over the next 10 years, multiplying the team size by five in five years (41 employees in 2020). 2M European people will benefit from the test in 2024. Amadix turnover in 2021 will be €18 m, which will give our company a profit of €7 m in 2021. From this year on the company will be profitable. Overall, ColoFast will reduce mortality rate and treatment cost while improving quality of life in a cost-effective way, assisting also to fulfill European priorities for healthcare improvements.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores